Medipal Holdings Corporation · TSE:7459
Medipal — Q3 FY2024 Earnings Presentation
22 slides from Medipal's earnings presentation, Feb 10, 2025
Slide 1: Financial Results for the 3rd Quarter Ended Dec. 31, 2024
Financial Results for the 3rd Quarter Ended Dec. 31, 2024 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being and to enhance its corporate value. Feb. 10, 2025 Forward-Looking St
Slide 2: Key Messages
Key Messages 2027 MEDIPAL Medium-Term Vision Oroshi Growing through business portfolio Change the 卸 Forever prioritizations and collaboration with partners 〜Constant Innovation〜 Growing steadily as a whole due to well-performed MEDICEO and PALTAC businesses. Profits increased significantly YoY due t
Slide 3: Contents
Contents １．Financial Results for the 3rd Quarter Ended Dec. 31, 2024 ２．Initiatives for the 3rd Quarter Ended Dec. 31, 2024 The MEDIPAL Group has three business segments: ・ Prescription Pharmaceutical Wholesale Business (MEDICEO Business) ・ Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesal
Slide 4: Consolidated Statements of Income
Consolidated Statements of Income (\ billion) 3Q/FY2023 3Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 2,714.9 2,807.1 +92.2 +3.4% Gross Profit 186.6 194.2 +7.5 +4.0% （6.88％） （6.92％） (＋0.04pp) SG&A Expenses 149.4 148.8 -0.６ -0.4% (5.50%） （5.30％） (-0.20pp
Slide 5: Consolidated Statements of Income [Change Factors from 3Q/FY2023]
Consolidated Statements of Income [Change Factors from 3Q/FY2023] Achieved Net Sales increase in all business segments and increased profits due to decrease in SG＆A expenses Adjusted operating profit, excluding the impact of business investment expenses, etc., also increased. Amount YoY Change Chang
Slide 6: Factors behind YoY changes in Gross Profit, Operating Profit and Ordinary Profit
Factors behind YoY changes in Gross Profit, Operating Profit and Ordinary Profit +3.24 Due to increased SG＆A expenses（Decrease） Non-Operating Income/Expenses ¥︓Billion sales of MEDISKET +0.60 -1.68 +4.31 Due to increased sales. ＋4.99 -1.1９ +8.15 +0.08 -2.06 +7.55 -3.20 Other factors Research fee inc
Slide 7: Factors behind YoY changes in Ordinary Profit, Profit before Income Taxes and Profit
Factors behind YoY changes in Ordinary Profit ,Profit before Income Taxes and Profit attributable to Owners of Parent ¥︓Billion Extraordinary Income/Expenses +5.74 +8.63 -1.22 -1.94 +0.27 +12.21 Gain on -3.72 step acquisitions Compensation Others income -0.53 +7.95 +6.46 Income taxes Profit rebound
Slide 8: Prescription Pharmaceutical Wholesale Business (MEDICEO Business)
Prescription Pharmaceutical Wholesale Business (MEDICEO Business) (\ billion) 3Q/FY2023 3Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 1,747.3 1,809.7 +62.3 +3.6% 108.0 113.7 +5.7 +5.3% Gross Profit (6.18%) （6.29%) (＋0.10pp) 95.0 92.9 -2.1 -2.2% SG&A Exp
Slide 9: MEDICEO Business [Change Factors from 3Q/FY2023]
MEDICEO Business [Change Factors from 3Q/FY2023] Exceeded the market growth, achieving increased sales and profits by utilizing unique functions “the two Aʼs (ALCs and ARs).," and the start of sales of covid-19 vaccines. ALC: Area Logistics Center, AR: Asist Representatives Amount YoY Change Change
Slide 10: Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business)
Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business (PALTAC Business) (\ billion) 3Q/FY2023 3Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 883.0 911.0 +28.0 +3.2% 66.3 68.0 +1.6 +2.5% Gross Profit (7.52%) (7.47%) (-0.05pp) 44.4 45.5 +1
Slide 11: PALTAC Business [Change Factors from 3Q/FY2023]
PALTAC Business [Change Factors from 3Q/FY2023] Exceeded Sales and Operating Profit YoY due to the successful sales expansion measures that captured the environmental change and an improvement in the SG&A ratio. Amount YoY Change Change factors from 3Q/FY2023 • Boosted demand on outing-related produ
Slide 12: Animal Health Products and Food Processing Raw Materials Wholesale (AGRO-FOOD Business)
Animal Health Products and Food Processing Raw Materials Wholesale and Related Business (AGRO・ FOOD Business) (\ billion) 3Q/FY2023 3Q/FY2024 Results Results YoY Change % of Change (% of Net Sales) (% of Net Sales) Net Sales 86.6 89.4 +2.7 +3.1％ 12.3 12.4 +0.1 +1.3% Gross Profit (14.22%) (13.97%) (-
Slide 13: AGRO-FOOD Business [Change Factors from 3Q/FY2023]
AGRO・ FOOD Business [Change Factors from 3Q/FY2023] Net Sales remained steady and Gross profit increased. Operating profit decreased due to the investments for the future growth, however the decrease was smaller than in 2Q. Amount YoY Change Change factors from 3Q/FY2023 • Animal Health Products who
Slide 14: Progress to the Full-year Consolidated Financial Forecast
＜Appendix＞ Progress to the Full-year Consolidated Financial Forecast ¥︓Billion Consolidated No revisions to full-year forecast Forecast for the Results for the FY2024 3Q/FY2024 Progress (% of Net (% of Net rate Sales） Sales） Net Sales 3,660.0 2,807.1 76.7% 【Operating Profit】 The forecast includes bu
Slide 15: Contents: Initiatives for the 3rd Quarter
Contents １．Financial Results for the 3rd Quarter Ended Dec. 31, 2024 ２．Initiatives for the 3rd Quarter Ended Dec. 31, 2024 Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 14
Slide 16: Started Promotion of ROHTO's AutoloGel System for Intractable Wounds
Started Promotion of ROHTOʼs AutoloGel System for Intractable Wounds Not only distribute, but also provide information through AR※1 and RD-MR※2. Contributing to QOL of patients with intractable wounds Distribution and Information activities Entrusted sales to medical for medical institutions profess
Slide 17: Joint Investment in Teva Takeda Pharma Ltd.
Joint Investment in Teva Takeda Pharma Ltd. Steadily deliver quality-assured generic drugs to patients Teva Takeda Pharma Ltd Nichi-Iko Pharmaceutical Co., Ltd. Scheduled to be completed MEDIPAL will invest 20% by Apr. 1, 2025 Teva Takeda Pharma Ltd. The company name is scheduled to change in Sep.,
Slide 18: JR-446: First Dosing in Phase I/II Clinical Trial
JR-446: First Dosing in Phase I/Ⅱ Clinical Trial Providing rare disease medicines for patients around the world who are in needs. Administered to the first patient in a Phase I/Ⅱ for mucopolysaccharidosis type ⅢB in Japan Mucopolysaccharidosis type ⅢB (Sanfilippo syndrome type B or MPS ⅢB) A type of
Slide 19: PALTAC Business Initiatives
PALTAC Business Initiatives Priority initiatives in line with "PALTAC VISION 2027“ - Constructing the foundation for transformation through structural reform - 【Enhancing delivery improvement】 Collaborating with delivery companies and retailers to achieve efficient and sustainable logistics 〜Jointly
Slide 20: Released Brand Website, Brand Video, and Official Social Media
Released Brand Website, Brand Video, and Official Social Media (SNS) Providing MEDIPAL Group's vision and activities for various stakeholders, leading to sustainable growth and improving corporate value Sharing information on the wide-ranging initiatives of our group companies such as sustainability
Slide 21: Management Philosophy
Management Philosophy Contributing to people’s health and the advancement of society through creation of value in distribution Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 20
Slide 22: Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved.
Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 21